Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke
Associated Therapies
-

Pharmacokinetic Interactions of Losartan and Hydrochlorothiazide

First Posted Date
2013-05-21
Last Posted Date
2013-05-27
Lead Sponsor
Damanhour University
Target Recruit Count
18
Registration Number
NCT01858623

Losartan in Decompensated Heart Failure

First Posted Date
2013-05-20
Last Posted Date
2013-05-20
Lead Sponsor
InCor Heart Institute
Target Recruit Count
21
Registration Number
NCT01857999
Locations
🇧🇷

Cotoxó Hospital, Heart Institute (InCor), University of São Paulo, São Paulo, SP, Brazil

The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2013-05-16
Last Posted Date
2022-07-11
Lead Sponsor
Fan Fan Hou
Target Recruit Count
238
Registration Number
NCT01854814
Locations
🇨🇳

Nanfang Hospital Southern Medical University, Guangzhou, Guangdong, China

🇨🇳

The Fourth People's Hospital Shenzhen, Shenzhen, Guangdong, China

🇨🇳

The Institute of Nephrology, Guangdong Medical College, Zhanjiang, Guangdong, China

Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV

Phase 2
Completed
Conditions
Interventions
First Posted Date
2013-05-14
Last Posted Date
2020-12-11
Lead Sponsor
University of Minnesota
Target Recruit Count
52
Registration Number
NCT01852942
Locations
🇺🇸

University of Minnesota, Division of Infectious Diseases, Minneapolis, Minnesota, United States

Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer

First Posted Date
2013-04-01
Last Posted Date
2020-09-25
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
50
Registration Number
NCT01821729
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD

First Posted Date
2013-03-11
Last Posted Date
2020-09-24
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
6
Registration Number
NCT01808196
Locations
🇺🇸

Kara Kliewer, Mason, Ohio, United States

Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma

Phase 3
Completed
Conditions
Interventions
First Posted Date
2013-03-06
Last Posted Date
2020-05-08
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
80
Registration Number
NCT01805453
Locations
🇫🇷

Neurology Department - Avicenne Hospital, Bobigny, France

Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers

First Posted Date
2013-01-11
Last Posted Date
2014-06-27
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
45
Registration Number
NCT01766050
Locations
🇺🇸

Healthcare Discoveries, Llc D/B/A Icon Development Solutions, San Antonio, Texas, United States

Study of Cardiovascular Disease and Obstructive Sleep Apnea

First Posted Date
2012-07-11
Last Posted Date
2020-08-14
Lead Sponsor
University of Wisconsin, Madison
Target Recruit Count
87
Registration Number
NCT01637623
Locations
🇺🇸

Marshfield Clinic, Marshfield, Wisconsin, United States

🇺🇸

Gundersen Lutheran, La Crosse, Wisconsin, United States

🇺🇸

Aurora Bay Care, Green Bay, Wisconsin, United States

and more 1 locations

Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients Not Controlled by Amlodipine

First Posted Date
2012-05-23
Last Posted Date
2016-02-01
Lead Sponsor
Hospital Universitario Pedro Ernesto
Target Recruit Count
30
Registration Number
NCT01603940
Locations
🇧🇷

Hospital Universitario Pedro Ernesto, Rio de Janeiro, RJ, Brazil

© Copyright 2024. All Rights Reserved by MedPath